跳至主要内容
临床试验/NCT01395602
NCT01395602已完成1 期

Randomized Controlled Pilot Study of the Effect of Cabergoline on Body Weight and Glucose Tolerance in Healthy Obese Adults

Columbia University1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2002年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
40
试验地点
1
主要终点
body weight

研究概览

简要总结

The aim of this study is to determine the efficacy of cabergoline, a long-acting dopamine receptor agonist, on body weight and blood glucose in healthy obese adults.

This is a randomized double-blind placebo controlled study. Twenty subjects each will be randomly assigned either placebo or cabergoline for 16 weeks.

The effect of treatment on body weight and blood glucose and insulin levels will be compared in the treatment versus the placebo arm.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • age 18 - 55 years
  • BMI 30 -40

排除标准

  • diabetes,
  • clinically significant medical condition,
  • use of medications that effect blood glucose or body weight

研究组 & 干预措施

placebo

Placebo Comparator

placebo pill

干预措施: placebo (Other)

cabergoline

Active Comparator

cabergoline pill

干预措施: Cabergoline (Drug)

结局指标

主要结局

body weight

时间窗: 16 weeks

次要结局

  • glucose(16 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Judith Korner

Associate Professor of Medicine

Columbia University

研究点 (1)

Loading locations...

相似试验

Effect of Cabergoline on Weight and Glucose Tolerance | 临床试验